SCHEMBL5542532

SCHEMBL5542532

C=C(C)Cn1c(=O)oc2ccccc21

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.65
MAPK1 P28482 3/20 0.62
TSHR P16473 2/20 0.62
USP2 O75604 1/20 0.62
ALDH1A1 P00352 4/20 0.60
HTT P42858 1/20 0.60
LMNA P02545 2/20 0.58
NPSR1 Q6W5P4 1/20 0.57
IDO1 P14902 2/20 0.56
CBX7 O95931 3/20 0.56
CDYL Q9Y232 3/20 0.56
MIF P14174 1/20 0.55
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
CDYL2 Q8N8U2 2/20 0.53
CDY1; CDY1B Q9Y6F8 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13995838 0.85 HPGD (0.71) HPGDMAPK1TSHRUSP2ALDH1A1
SCHEMBL5537191 0.82 ALDH1A1 (0.68) HPGDMAPK1TSHRUSP2ALDH1A1
SCHEMBL27210129 0.81 HTT (0.44) HPGDTSHRALDH1A1HTTLMNA
SCHEMBL29811259 0.81 HTT (0.44) HPGDTSHRALDH1A1HTTLMNA
SCHEMBL5548457 0.81 ALDH1A1 (0.70) HPGDMAPK1TSHRUSP2ALDH1A1
SCHEMBL2947194 0.80 HPGD (0.73) HPGDMAPK1TSHRUSP2ALDH1A1
SCHEMBL14667473 0.79 HPGD (0.58) HPGDMAPK1TSHRUSP2ALDH1A1
SCHEMBL4412637 0.79 MEN1 (0.63) HPGDMAPK1TSHRUSP2ALDH1A1
SCHEMBL4414345 0.79 HPGD (1.00) HPGDMAPK1TSHRUSP2ALDH1A1
SCHEMBL6717405 0.78 HPGD (0.66) HPGDMAPK1TSHRUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HPGD 3159/4885MAPK1 1392/4885TSHR 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.